CompletedPhase 3

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

Côte d’Ivoire167 participantsStarted 2018-10-01

Plain-language summary

An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire This study aims to determine the efficacy of repeated (up to four times) praziquantel treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive antigen- and DNA-detection methods.

Who can participate

Age range5 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at least one positive out of triplicate Kato-Katz thick smears) * Subject is aged between 5 and 18 years and otherwise in good health * Subject has received no recent praziquantel treatment in the past month * Subject has provided oral assent and provided written informed consent signed by parents/legal guardian * Subject is able and willing to provide multiple stool and urine samples during study Exclusion Criteria: * Known allergy to study medication (i.e. praziquantel and albendazole) * Pregnancy * Lactating

What they're measuring

Cure rate

Timeframe: 8 weeks

Trial details

NCT IDNCT02868385

SponsorLeiden University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01-14

View on ClinicalTrials.gov More Schistosomiasis trials